Pascolizumab

DB06560InvestigationalProtein Based Therapies

Pascolizumab (SB 240683) is a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.

Mechanism: Pascolizumab is a humanized anti-IL-4 monoclonal antibody that can inhibit upstream and downstream events associated with asthma, including (T(H)2) cell activation and immunoglobulin E production.
Curator reviewed
Primary indication: Investigated for use/treatment in asthma.Curator reviewed
Code names: SB-240683

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Pascolizumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.